New Hypertension Drug Shows Promise for Kidney Patients
A new treatment could lower blood pressure and improve kidney markers for adults managing chronic disease.
Updated on Oct. 22, 2026 in Heart Disease
Live Poll
Do you trust that new pharmaceutical treatments for chronic conditions effectively improve patient long-term health?
Data from the Phase 3 Launch-HTN trial show that the investigational drug lorundrostat significantly reduced systolic blood pressure and kidney-related markers in adults with chronic kidney disease. The findings, presented at the American Society of Nephrology Kidney Week conference, offer a potential new treatment path for patients struggling with uncontrolled hypertension.
Why it matters
Uncontrolled hypertension remains a primary driver of heart and kidney damage, contributing to nearly 700,000 deaths annually in the U.S. This new therapy targets dysregulated aldosterone levels, a specific biological mechanism that complicates blood pressure management in patients with underlying kidney issues.
In a Phase 3 trial involving adults with uncontrolled blood pressure, lorundrostat achieved a 9.6 mmHg reduction in systolic blood pressure for those with chronic kidney disease versus placebo at 12 weeks. Additionally, participants with baseline albuminuria saw a 52.2% reduction in urine albumin-to-creatinine ratio compared to the placebo group.
The players
Mineralys Therapeutics
A biopharmaceutical company based in Radnor, Pennsylvania, focused on developing therapies for hypertension and related conditions.
American Society of Nephrology
A global organization that advances kidney health through education and research, hosting the annual Kidney Week conference.
The details
Lorundrostat functions as an aldosterone synthase inhibitor designed to lower aldosterone levels, a hormone that regulates salt and water balance. By selectively inhibiting this enzyme, the drug addresses the hormonal imbalances that often drive resistant hypertension. The trial utilized daily oral dosing of either 50 mg or a titrated 100 mg dose, measuring results against a placebo to determine its impact on vascular pressure and kidney health markers.
Timeline
October 22, 2026: Clinical trial data were presented at the ASN Kidney Week conference.
December 22, 2026: The FDA is scheduled to complete its review of the drug.
Health Landscape
This development addresses a critical gap in treating patients who struggle to maintain stable blood pressure despite current standard-of-care medications. It reflects a shift toward precision therapies that target specific hormonal pathways rather than relying solely on broad-spectrum antihypertensives.
If you are currently managing uncontrolled high blood pressure alongside chronic kidney disease, these results provide a specific development to track as the drug moves through regulatory review. It is worth discussing with your cardiologist or nephrologist whether your current treatment plan addresses aldosterone-driven hypertension.
The takeaway
This trial highlights that targeting aldosterone may be an effective strategy for lowering blood pressure in patients with kidney complications. Continue monitoring your blood pressure at home and consider discussing new therapeutic options with your physician to ensure your current medication remains optimal.
What happens next
The FDA is expected to complete its formal review of lorundrostat by December 22, 2026.
Further reading
For more on the current standard of care and emerging options, visit the Heart Disease section.
Live Poll
Do you trust that new pharmaceutical treatments for chronic conditions effectively improve patient long-term health?
